Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001068 | 0.84 | SMN1; SMN2 (0.50) | PLCG1SMN1; SMN2L3MBTL1KCNN4TSHR | |
| SCHEMBL9978324 | 0.84 | SMN1; SMN2 (0.46) | PLCG1SMN1; SMN2L3MBTL1KCNN4TSHR | |
| SCHEMBL1027526 | 0.83 | AHR (0.46) | PLCG1SMN1; SMN2L3MBTL1KCNN4AHR | |
| SCHEMBL28403522 | 0.82 | SMN1; SMN2 (0.47) | PLCG1SMN1; SMN2L3MBTL1KCNN4AHR | |
| SCHEMBL3134099 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1CYP19A1TSHRBLM | |
| SCHEMBL20166133 | 0.81 | AHR (0.47) | PLCG1SMN1; SMN2L3MBTL1KCNN4AHR | |
| SCHEMBL10334728 | 0.81 | SMN1; SMN2 (0.46) | PLCG1SMN1; SMN2L3MBTL1KCNN4AHR | |
| SCHEMBL12928720 | 0.79 | L3MBTL1 (0.52) | SMN1; SMN2L3MBTL1TSHRBLMCYP2D6 | |
| SCHEMBL505194 | 0.79 | L3MBTL1 (0.52) | SMN1; SMN2L3MBTL1TSHRBLMCYP2D6 | |
| SCHEMBL5700780 | 0.79 | SMN1; SMN2 (0.44) | PLCG1SMN1; SMN2L3MBTL1KCNN4AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273129-A1 | RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2022-11-17 | — | — | US | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143771-A1 | RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685363-A | ROR gamma t regulator, preparation method and application thereof | 上海医药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-107873023-B | 3-alkyl-4-amido-bicyclo [4, 5, 0] hydroxamic acids as HDAC inhibitors | 福马治疗股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | PLCG1 4608/4885SMN1; SMN2 911/4885L3MBTL1 178/4885 |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | PLCG1 1470/4885SMN1; SMN2 184/4885L3MBTL1 3924/4885 |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | REN, AGTR1, ADH1A | PLCG1 4449/4885SMN1; SMN2 4687/4885L3MBTL1 3039/4885 |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORC, RORB, RORA | PLCG1 2220/4885SMN1; SMN2 4471/4885L3MBTL1 4147/4885 |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | PLCG1 4608/4885SMN1; SMN2 911/4885L3MBTL1 178/4885 |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | PLCG1 4608/4885SMN1; SMN2 911/4885L3MBTL1 178/4885 |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | PLCG1 3849/4885SMN1; SMN2 3838/4885L3MBTL1 1809/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | PLCG1 4813/4885SMN1; SMN2 4528/4885L3MBTL1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.